[1] |
CHEN Yuyan, ZHANG Mingxia, ZHANG Tao, ZHANG Jin.
One case of interstitial pneumonia caused by serplulimab injection
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 213-215.
|
[2] |
CAO Guiping, DENG Linlin, ZHU Ganhong, LU Ying, MA Shuang, CHEN Linlin, Liu Lili.
One case of severe liver injury caused by Tianma Shouwu tablets
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 216-218.
|
[3] |
WANG Xin, SHI Leilei, ZHANG Yuhan, XIE Yundong, LIU Jiping.
The role of MRPs transporters in drug-induced liver injury
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 229-234.
|
[4] |
GUO Longxin, GAO Yunjuan, WU Chengzhao, LONG Minjuan, ZHU Shengkai, SONG Haibo, ZHAO Xu, XIAO Xiaohe.
Exploring new risk signals and susceptibility factors of traditional Chinese medicine-induced hepatotoxicity based on big data from adverse reaction monitoring
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(1): 15-19.
|
[5] |
ZHANG Liangliang, HU Changkun, WU Zekun, ZHOU Wei, LIAO Zebin, GAO Yue.
Protective effect and mechanism of dimethyl fumarate against intestinal radiation injury
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(1): 83-88.
|
[6] |
BUCHANAN James.
Assessment of drug-induced liver injury via nR modified Hy’s law and PALT
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(1): 117-120.
|
[7] |
ZHANG Qi, CHEN Min, ZHANG Shiqing.
Conditional approval of medical devices in the United States and enlightenment
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(9): 1007-1010.
|
[8] |
LI Jing, XU Ye, LIU Ranjia, PAN Chen, CUI Xiangli.
Adverse reactions in patients with COVID-19 after using tocilizumab
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(9): 1049-1053.
|
[9] |
ZAN Ke, ZHAO Lei, JIANG Dacheng, WANG Ying, JIN Hongyu, MA Yu, MA Shuangcheng.
Determination of 135 pesticide residues in Farfarae Flos by UPLC-MS/MS and risk assessment
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(8): 885-890.
|
[10] |
WANG Ran, LI Yifan, LIU Xiaoyan, FENG Xin.
One case of pharmaceutical care of drug exposure during pregnancy
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(8): 933-934.
|
[11] |
WANG Ran, FENG Xin, DU Boran.
Advances in risk assessment and pharmaceutical care of pregnancy medication exposure during perinatal period
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(7): 836-840.
|
[12] |
CHEN Chongze, LI Jie, KUANG Lian, TAN Xuewen, LIU Minhui, LIU Xi, ZHENG Yanchai, JIN Hongtao.
Characterization of adverse reactions associated with drug-induced liver injury in 448 inpatients
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(6): 697-704.
|
[13] |
YU Lecheng, HAO Kunyan, FAN Ye.
Clinical diagnosis of Chinese-herbal-induced liver injury
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(5): 481-488.
|
[14] |
ZHU Chunwu, YU Xuejun, SUN Xin, LIU Chenghai.
Overview of hepatotoxicity of Xianling Gubao capsules
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(5): 496-499.
|
[15] |
LUO Qiong, LI Meng, LI Guangyao, HE Yanchun, ZHOU Zushan, SUN Xin, LIU Chenghai.
Chinese medical evidence and characteristics of combined medication in 635 cases of rheumatoid arthritis patients with liver injury caused by the application of Tripterygium wilfordii preparations
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(5): 500-504.
|